Novavax (NVAX) Tops Q2 EPS by 68c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $9.00 -1.42%
EPS Growth %: -164.5%
Financial Fact:
General and administrative: 13.56M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -164.5%
Financial Fact:
General and administrative: 13.56M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q2 EPS of $0.62, $0.68 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $239 million versus the consensus estimate of $156.23 million.
GUIDANCE:
Novavax sees Q3 2025 revenue of $495-545 million, versus the consensus of $89.61 million.
Novavax sees FY2025 revenue of $1-1.05 billion, versus the consensus of $1.02 billion.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- Apollo Private Credit Fund caps redemptions at 5% - Bloomberg
- AeroVironment restates quarterly financials, citing $89M goodwill error
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
